Pharma stock falls 6% after FSDA suspends cough syrup production
pre-market1 source ↓written by the desknot a recommendation
- to ₹803 following
- 6%
- this fiscal
- ₹55.21 cr
- Despite
- 19% YoY revenue increase
- cap stands
- ₹1,700 cr
Windlas Biotech's shares dropped 6% to ₹803 following a show-cause notice from FSDA, suspending its codeine-based cough syrup manufacturing. This segment contributed ₹55.21 cr this fiscal. Despite a 19% YoY revenue increase, investor sentiment is dampened by regulatory uncertainty. The company's market cap stands at ₹1,700 cr.
Not investment advice. For informational purposes only.